Jiuliang Yan
Overview
Explore the profile of Jiuliang Yan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie P, Wu M, Wang H, Zhang B, Zhang Z, Yan J, et al.
Oncogene
. 2024 Sep;
43(42):3108-3120.
PMID: 39251847
Lenvatinib is a multiple receptor tyrosine kinases inhibitor (TKI) authorized for first-line treatment of hepatocellular carcinoma (HCC). However, Lenvatinib resistance is common in HCC clinical treatment, highlighting the urgent need...
2.
Chen Z, Yu M, Zhang B, Jin L, Yu Q, Liu S, et al.
Oncoimmunology
. 2024 Jul;
13(1):2376264.
PMID: 38988824
Functional roles of SIGLEC15 in hepatocellular carcinoma (HCC) were not clear, which was recently found to be an immune inhibitor with similar structure of inhibitory B7 family members. SIGLEC15 expression...
3.
Yan J, Wang X, Fan Z, Xu Y, Zhang Y, Liu Y, et al.
Apoptosis
. 2024 Mar;
29(5-6):709-725.
PMID: 38459420
Hepatocellular carcinoma (HCC) is highly metastatic and invasive. CircRNA participates in gene regulation of multiple tumor metastases, but little is known whether it is a bystander or an actual player...
4.
Xie P, Yu M, Zhang B, Yu Q, Zhao Y, Wu M, et al.
J Hepatol
. 2024 Feb;
81(1):93-107.
PMID: 38403027
Background & Aims: The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed...
5.
Wu C, Hu B, Wang L, Wu X, Gu H, Dong H, et al.
iScience
. 2023 Jan;
26(1):105723.
PMID: 36590169
Lipid metabolism is extensively reprogrammed in pancreatic ductal adenocarcinoma (PDAC). Stearoyl-coenzyme A desaturase (SCD) is a critical lipid regulator that was unexplored in PDAC. Here, we characterized the existence of...
6.
Chang H, Jin L, Xie P, Zhang B, Yu M, Li H, et al.
J Gastrointest Oncol
. 2022 Nov;
13(5):2351-2365.
PMID: 36388659
Background: Colorectal cancer (CRC) is one of the most prominent malignant diseases, with a high incidence and a dismal prognosis. Metastasis to the liver is the leading cause of death...
7.
Xu M, Yan J, Hu B, Wu C, Gu H, Qi Z, et al.
Genes (Basel)
. 2022 Sep;
13(9).
PMID: 36140756
Liver metastases are common in pancreatic neuroendocrine tumors (PanNETs) patients and they are considered a poor prognostic marker. This study aims to analyze the spatiotemporal patterns of genomic variations between...
8.
Xie P, Yan J, Wu M, Li H, Chen Z, Yu M, et al.
Ann Transl Med
. 2022 Jul;
10(12):689.
PMID: 35845518
Background: Cell adhesion molecule cluster of differentiation 44 (CD44) plays a significant role in cancer cell local invasion, intravasation, migration, and the establishment of metastatic lesions. However, little is known...
9.
Hu B, Wu C, Mao H, Gu H, Dong H, Yan J, et al.
Ann Transl Med
. 2022 Apr;
10(5):262.
PMID: 35402584
Background: Cancer-associated fibroblasts (CAFs) are a vital constituent of the tumor microenvironment (TME) and have several activities, but the effect of CAF heterogeneity on the molecular features and clinical outcomes...
10.
Chen Z, Liu S, Xie P, Zhang B, Yu M, Yan J, et al.
Biochem Biophys Res Commun
. 2022 Mar;
605:82-89.
PMID: 35316767
Backgrounds: Autophagy in tumor was also found to influence immune microenvironment. The relation between autophagy and cancer intrinsic PD1 and PD-L1 expression was not clear. Methods: With data from TCGA...